Holen Sie sich die Stockscreener-App
2.24
2.75%
0.06
Handel nachbörslich:
2.25
0.010
+0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.18
Offen:
$2.16
24-Stunden-Volumen:
8.06M
Relative Volume:
0.59
Marktkapitalisierung:
$889.21M
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-1.8211
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
-9.31%
1M Leistung:
-1.32%
6M Leistung:
+27.64%
1J Leistung:
-72.82%
1-Tages-Spanne:
$2.09
$2.25
1-Wochen-Bereich:
$2.09
$2.62
52-Wochen-Spanne:
$1.6385
$9.70
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.24 | 865.39M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail
Iovance (NASDAQ: IOVA) grants inducement stock options on 164,900 shares at $2.18 - Stock Titan
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Strategies to average down on Iovance Biotherapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
Can Iovance Biotherapeutics Inc. stock deliver sustainable ROEJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Why Iovance Biotherapeutics Inc. stock appeals to analystsJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Is Iovance Biotherapeutics Inc. (2LB) stock overpriced at current multiplesJuly 2025 Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersJuly 2025 Short Interest & Weekly Chart Analysis and Guides - newser.com
Can Iovance Biotherapeutics Inc. (2LB) stock resist broad market declinesJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Iovance Biotherapeutics: Investigation and Financial Strategies - StocksToTrade
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsQuarterly Growth Report & Accurate Trade Setup Notifications - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock attracts wealthy investors - newser.com
Why Iovance Biotherapeutics Inc. stock attracts global investorsJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com
Published on: 2025-11-19 04:39:30 - newser.com
Published on: 2025-11-19 00:55:20 - newser.com
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stock2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):